List of Excipients in Branded Drug GENVOYA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Gilead Sciences Inc	GENVOYA	elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide	61958-1901	CELLULOSE, MICROCRYSTALLINE	2027-04-26
Gilead Sciences Inc	GENVOYA	elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide	61958-1901	CROSCARMELLOSE SODIUM	2027-04-26
Gilead Sciences Inc	GENVOYA	elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide	61958-1901	FD&C BLUE NO. 2	2027-04-26
Gilead Sciences Inc	GENVOYA	elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide	61958-1901	FERRIC OXIDE YELLOW	2027-04-26
Gilead Sciences Inc	GENVOYA	elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide	61958-1901	HYDROXYPROPYL CELLULOSE	2027-04-26

Genvoya Excipient Strategy and Commercial Opportunities

Last updated: October 3, 2026

Genvoya is a fixed-dose HIV-1 treatment containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide. Its excipient system supports a high-load, immediate-release, film-coated tablet with chemical protection for moisture-sensitive components and acceptable manufacturability. The main commercial opportunities are generic or regional co-formulated products, excipient and process packages for TAF-based tablets, and differentiated formulations that preserve the four-drug regimen while improving cost, size, stability, or supply resilience.

What is Genvoya and which active ingredients must the excipient system support?

Genvoya is marketed by Gilead Sciences as a once-daily oral tablet for the treatment of HIV-1 infection in eligible patients. Each tablet contains:

Active ingredient	Amount per tablet	Functional role
Elvitegravir	150 mg	Integrase strand-transfer inhibitor
Cobicistat	150 mg	Pharmacokinetic enhancer
Emtricitabine	200 mg	Nucleoside reverse transcriptase inhibitor
Tenofovir alafenamide	10 mg	Tenofovir prodrug and NRTI

The total active pharmaceutical ingredient load is 510 mg before excipients and coating. That load creates direct-compression and tablet-size constraints. TAF is present at a low dose but is commercially important because its stability, solid-state behavior, and regulatory characterization can influence product performance.

Genvoya was approved by the U.S. Food and Drug Administration in November 2015. The product is a small-molecule combination product, not a biologic. Biosimilar pathways therefore do not apply. FDA approval is based on an NDA, while generic competitors would generally use an abbreviated new drug application, subject to applicable patent and exclusivity barriers (FDA, 2015).

What excipients are used in Genvoya tablets?

Genvoya’s U.S. labeling identifies a conventional immediate-release tablet excipient system. The tablet core contains:

• Lactose monohydrate
• Microcrystalline cellulose
• Croscarmellose sodium
• Hydroxypropyl cellulose
• Silicon dioxide
• Sodium lauryl sulfate
• Magnesium stearate

The film coating contains:

• Polyvinyl alcohol
• Titanium dioxide
• Polyethylene glycol
• Talc
• Iron oxide yellow

The qualitative formulation is disclosed in the prescribing information. The commercial quantitative formulation, including the amount of each excipient and the manufacturing process parameters, is not generally disclosed in the label (Gilead Sciences, 2024).

What does each Genvoya excipient do?

Excipient	Primary formulation function	Strategic relevance
Lactose monohydrate	Diluent and compressibility aid	Supports tablet mass and powder flow; may require lactose compatibility controls
Microcrystalline cellulose	Diluent, dry binder, compression aid	Helps achieve tablet strength at high API loading
Croscarmellose sodium	Superdisintegrant	Promotes rapid tablet breakup and dissolution
Hydroxypropyl cellulose	Binder and granulation aid	Supports granule strength and content uniformity
Silicon dioxide	Glidant and moisture-control aid	Improves powder flow and reduces manufacturing variability
Sodium lauryl sulfate	Wetting and surfactant agent	Can improve dissolution of poorly wettable components
Magnesium stearate	Lubricant	Controls ejection force but can impair dissolution if over-lubrication occurs
Polyvinyl alcohol	Film-forming polymer	Provides a robust immediate-release coating
Titanium dioxide	Opacifier and pigment	Supports coating appearance and light protection
Polyethylene glycol	Plasticizer	Reduces coating brittleness
Talc	Anti-tacking and coating aid	Improves coating processability
Iron oxide yellow	Colorant	Provides product identification and visual differentiation

The excipient system is commercially conservative. It uses widely established pharmaceutical excipients rather than novel delivery technologies. That reduces regulatory risk but limits differentiation based solely on inactive ingredients.

How does Genvoya’s formulation strategy affect manufacturing?

Genvoya presents four major manufacturing challenges.

High total tablet load

The 510 mg active load is high for a once-daily fixed-dose tablet. Developers must balance tablet size, hardness, friability, disintegration, and dissolution. Increasing compression force can improve mechanical strength but may slow disintegration and dissolution.

Low-dose TAF and cobicistat uniformity

TAF is present at 10 mg per tablet, while the other active ingredients are present at materially higher levels. Low-dose TAF creates content-uniformity risk, especially if the process relies on direct blending rather than controlled granulation or engineered API particle distribution.

Cobicistat is present at 150 mg and has a strong effect on the pharmacokinetic profile of elvitegravir. Uniform distribution of cobicistat is therefore a product-performance issue, not only a manufacturing issue.

Multi-API compatibility

The four active ingredients have different physicochemical characteristics. A generic developer must evaluate:

• Moisture sensitivity
• Particle-size distribution
• Bulk density
• Electrostatic behavior
• Segregation
• Lubricant sensitivity
• Chemical degradation
• Interaction with surfactants and polymers
• Solid-state transformation during granulation or compression

A common commercial strategy is to develop separate API-containing premixes or granules before final blending. That approach can improve content uniformity but adds process steps and validation burden.

Coating and stability

The film coat must protect tablet appearance and support stability without materially delaying release. TAF-containing products require careful evaluation of moisture exposure, packaging configuration, and accelerated stability. Aluminum-aluminum blister packaging or high-barrier bottles may be considered where stability data justify the added cost.

What excipient strategies are available for Genvoya competitors?

A competitor can pursue three broad excipient strategies.

Strategy 1: Formulation replication

The developer uses the same or functionally equivalent excipient classes as Genvoya. This approach minimizes development risk and supports conventional immediate-release performance.

Advantages include:

• Familiar regulatory profile
• Established supplier base
• Lower formulation complexity
• Straightforward dissolution development
• Easier scale-up

The main limitation is the need to avoid copying any protected manufacturing process or formulation claim. Excipients themselves are generally not a barrier when used in conventional quantities, but a specific combination, ratio, coating system, or process may fall within a patent claim.

Strategy 2: Excipient substitution

The developer replaces one or more excipients while preserving tablet performance. Potential substitutions include:

• Mannitol, dibasic calcium phosphate, or other diluents in place of lactose
• Crospovidone or sodium starch glycolate in place of croscarmellose sodium
• Povidone or copovidone in place of hydroxypropyl cellulose
• Colloidal silicon dioxide from an alternative supplier
• Alternative film-forming systems that avoid titanium dioxide or talc

Substitution can address lactose intolerance concerns, regional excipient restrictions, supplier shortages, cost pressure, or environmental objectives. It also creates a distinct formulation profile that may reduce literal overlap with formulation patent claims.

The risk is that substitution changes powder flow, compaction, dissolution, impurity formation, or stability. A formulation that appears chemically equivalent may still require extensive comparative development.

Strategy 3: Process-led differentiation

The developer retains conventional excipients but uses a different manufacturing platform, such as:

• Dry granulation
• Roller compaction
• Wet granulation
• Co-processing of diluent and disintegrant
• Ordered mixing for low-dose TAF
• Continuous manufacturing
• Spray-dried API or excipient intermediates
• Tablet-in-tablet or multilayer compression

Process-led differentiation can reduce tablet weight and improve uniformity. It may also create manufacturing or process patent opportunities. The tradeoff is higher scale-up and validation risk.

What commercial opportunities exist for Genvoya excipient suppliers?

The largest near-term opportunity is not a novel excipient. It is supply and technical support for generic and regional versions of a complex fixed-dose combination.

Excipient supply contracts

A Genvoya-like formulation uses several high-volume excipients with established global suppliers. Suppliers can compete on:

• Pharmaceutical grade and compendial compliance
• Consistent particle-size distribution
• Low bioburden and endotoxin controls
• Moisture specification
• Supply continuity
• Regional manufacturing capacity
• Change-control performance
• Technical documentation

For generic developers, supplier qualification is a significant part of the development timeline. Excipient vendors that provide robust regulatory packages and formulation support can secure preferred status.

Co-processed excipients

Co-processed filler-binder systems may improve flow and compressibility in a high-load, multi-API tablet. A supplier could position a custom or semi-custom platform around:

• Improved content uniformity
• Reduced lubricant sensitivity
• Lower compression force
• Smaller tablet dimensions
• Faster disintegration
• Better continuous-manufacturing performance

The commercial value depends on whether the platform produces a measurable advantage in the final tablet rather than only in placebo blends.

Film-coating systems

Ready-to-use film-coating systems can reduce development time and manufacturing variability. Opportunities include coatings that:

• Reduce coating weight
• Improve moisture barrier performance
• Avoid titanium dioxide
• Use globally accepted colorants
• Support high-speed coating
• Reduce solvent or water exposure
• Improve visual differentiation among regional products

A coating supplier can also provide color-matching and process-transfer services to generic manufacturers.

TAF-compatible formulation services

Because TAF is a relatively low-dose but strategically important component, contract development organizations can offer specialized services for:

• Low-dose content uniformity
• Moisture and impurity control
• API particle engineering
• Blend segregation studies
• Stability-indicating methods
• Packaging selection
• Comparative dissolution

These services are more defensible commercially than commodity excipient sales because they combine formulation know-how with regulatory execution.

What patents protect Genvoya and when could generic entry occur?

Genvoya’s commercial exclusivity depends on a combination of FDA regulatory exclusivity, Orange Book-listed patents, and the patent positions covering its active ingredients, combinations, formulations, and manufacturing processes.

The relevant patent categories are:

Patent category	Potential subject matter	Generic impact
Combination patents	Elvitegravir, cobicistat, emtricitabine, and TAF in one dosage form	May delay approval or require a Paragraph IV challenge
TAF patents	TAF composition, prodrug chemistry, salts, formulations, or uses	Can affect products containing TAF
Elvitegravir and cobicistat patents	Active compounds and pharmacokinetic enhancement	May create overlapping rights
Formulation patents	Excipient combinations, release characteristics, stability, or tablet architecture	May require a design-around
Method-of-use patents	HIV treatment regimens and patient populations	May create skinny-label or carve-out issues
Manufacturing patents	Processes for producing or formulating the combination	Can affect commercial supply even if product claims are avoided

Genvoya’s five-year anniversary passed in 2020, eliminating any remaining new chemical entity exclusivity that might have applied to the product. That does not eliminate patent-based barriers. Orange Book-listed patents and related TAF or combination patents remain the central legal issues for generic entry (FDA, 2024a).

An ANDA applicant may file a Paragraph IV certification asserting that a listed patent is invalid, unenforceable, or will not be infringed. The first eligible Paragraph IV filer may receive 180-day generic exclusivity if statutory requirements are met. Litigation can trigger a 30-month stay of FDA approval under the Hatch-Waxman framework, subject to statutory exceptions and court developments (Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355).

Exact entry timing depends on the current Orange Book listings, patent-term adjustments, pediatric extensions, litigation outcomes, settlements, and the applicant’s certification strategy. A commercial forecast should therefore model multiple launch dates rather than rely on the product approval date alone.

What is the Orange Book status of Genvoya?

Genvoya is listed in FDA’s Orange Book as an NDA product. The Orange Book identifies patents and exclusivity information submitted by the NDA holder for eligible products. Its listings can change as patents are added, delisted, corrected, or affected by litigation.

For commercial diligence, the relevant checks are:

1. Current Genvoya NDA listing.
2. Listed patent numbers and expiration dates.
3. Pediatric exclusivity, if applicable.
4. Any first-filer or 180-day exclusivity information.
5. ANDA applicants and certification status.
6. Patent litigation and settlement records.
7. Whether a competitor has carved out a patented method of use.

The Orange Book is the controlling public source for FDA-listed product patents. Patent-family databases should be used separately to identify related continuation, divisional, foreign, and non-Orange-Book rights (FDA, 2024a).

Which companies are most likely to challenge Genvoya?

Potential challengers include large generic companies with HIV portfolios, global suppliers of antiretroviral medicines, and regional manufacturers with established fixed-dose combination capabilities. The most credible candidates are companies with:

• Existing TAF or tenofovir manufacturing capability
• Experience with multi-API tablets
• HIV regulatory and pharmacokinetic expertise
• Ability to conduct comparative dissolution and bioequivalence work
• Sufficient capital for Paragraph IV litigation
• Distribution access in the United States, Europe, or high-volume emerging markets

A generic entrant must solve more than API sourcing. It must demonstrate bioequivalence for a four-component product, manage complex analytical methods, address impurity profiles, and maintain supply continuity across four active ingredients.

What generic launch scenarios exist for Genvoya?

At-risk launch

A company launches before final resolution of patent litigation. This can produce significant revenue if successful but exposes the applicant to damages, injunction risk, and loss of market access.

First-filer launch

A qualified first Paragraph IV applicant may obtain 180-day exclusivity. The commercial value depends on the number of first filers, settlement terms, forfeiture events, and the scope of the challenged patents.

Authorized generic or settlement launch

The branded company may authorize a generic or agree to a delayed launch. Settlement terms can include launch dates, licenses, supply arrangements, or restrictions on formulation and indication.

Post-expiry multi-generic launch

After the relevant patents expire or are invalidated, several ANDA holders may enter. This scenario generally produces rapid price erosion, especially where the product has no differentiated delivery system.

Regional launch

Companies may commercialize equivalent products outside the United States where patent coverage, regulatory requirements, and procurement systems differ. Public-sector HIV programs may create volume opportunities, but pricing is typically lower than in commercial markets.

How strong is the Genvoya patent estate?

The estate is strongest where rights cover TAF chemistry, the specific four-drug combination, or manufacturing processes that are difficult to design around. Conventional excipient claims are less commercially durable if a competitor can preserve bioequivalence with a substituted excipient system.

Patent strength should be assessed across four dimensions:

Dimension	Strong position	Weaker position
Composition	Narrowly defined but validated combination with clear infringement path	Broad claim vulnerable to prior-art or written-description challenges
Formulation	Demonstrated stability, dissolution, or bioavailability advantage	Conventional excipients with limited technical effect
Method of use	Clearly approved indication and enforceable claim scope	Overlapping treatment claims or carve-out availability
Manufacturing	Economically difficult process to replicate	Easily substituted granulation or blending process

The strongest design-around opportunity is usually excipient and process substitution, provided the resulting product meets bioequivalence and stability requirements.

What is Genvoya’s revenue exposure and competitive position?

Genvoya is part of Gilead’s broader HIV franchise, which includes Biktarvy, Descovy, Odefsey, and other products. Its commercial position is exposed to internal product substitution as well as external generic entry.

Biktarvy has become a major commercial competitor within Gilead’s HIV portfolio, while Genvoya remains relevant for patients and prescribers using an elvitegravir-based regimen. Revenue analysis should separate:

• Genvoya product sales
• HIV franchise sales
• Patient switching to Biktarvy
• Price erosion after generic entry
• Geographic sales concentration
• Public-sector versus private-sector demand
• Net price after rebates and discounts

Gilead reports HIV product revenue in its annual filings, but product-specific revenue and regional disclosures may vary by reporting period. A forecast should use the latest annual report and quarterly filings rather than historical peak sales alone (Gilead Sciences, 2024).

How does Genvoya compare with other fixed-dose HIV products?

Product	Core regimen	Key formulation issue	Competitive implication
Genvoya	Elvitegravir/cobicistat/emtricitabine/TAF	High-load four-API tablet and pharmacokinetic enhancer	Complex generic development
Biktarvy	Bictegravir/emtricitabine/TAF	Three-API tablet with TAF stability requirements	Strong internal substitute
Odefsey	Rilpivirine/emtricitabine/TAF	Food and formulation considerations	Different patient and prescribing profile
Stribild	Elvitegravir/cobicistat/emtricitabine/TDF	Earlier tenofovir formulation	Legacy product and distinct safety profile
Descovy-based combinations	Emtricitabine/TAF with another agent	TAF platform and co-formulation compatibility	Broadens TAF manufacturing experience

Genvoya has greater formulation complexity than a two- or three-component tablet, but the fixed-dose regimen can make it attractive to generic developers once legal barriers decline.

Key Takeaways

• Genvoya contains four active ingredients with a 510 mg total API load.
• Its excipient system is conventional and includes lactose, microcrystalline cellulose, croscarmellose sodium, hydroxypropyl cellulose, silicon dioxide, sodium lauryl sulfate, magnesium stearate, and a polyvinyl alcohol-based film coating.
• The primary formulation risks are multi-API compatibility, low-dose TAF uniformity, tablet size, moisture control, and dissolution reproducibility.
• The strongest commercial opportunities are in excipient supply, co-processed compression systems, film coatings, TAF-focused development services, and regional generic products.
• Genvoya is a small-molecule product, so biosimilar competition is irrelevant.
• FDA exclusivity no longer provides the principal barrier; Orange Book patents, TAF-related rights, combination claims, method-of-use claims, and manufacturing patents are more important.
• Generic launch timing depends on patent certifications, Paragraph IV litigation, settlements, patent-term adjustments, and regional rights.
• Excipient and process substitution can support design-around strategies, but only if bioequivalence, stability, dissolution, and content uniformity are preserved.

FAQs About Genvoya Excipient and Commercial Strategy

Can a generic Genvoya use different excipients?

Yes. A generic product can use different inactive ingredients if it meets FDA requirements for safety, pharmaceutical equivalence, bioequivalence, quality, and performance. The developer must also evaluate whether the alternative formulation avoids protected formulation or process claims.

Is TAF the main excipient-development challenge in Genvoya?

No. TAF is an active ingredient, not an excipient. It is, however, a major formulation-development focus because it is present at a low dose and can create content-uniformity, stability, impurity, and moisture-control challenges.

Does Genvoya require a biosimilar application?

No. Genvoya contains chemically synthesized small molecules. A competitor would generally pursue an ANDA or another applicable generic pathway, not a biosimilar application.

Can lactose-free Genvoya alternatives be developed?

Yes. Lactose can potentially be replaced with another diluent, such as mannitol or dibasic calcium phosphate, subject to compatibility, dissolution, compression, stability, and regulatory testing. The substitution may increase tablet weight or alter mechanical properties.

Which formulation improvement has the greatest commercial value?

A smaller, stable tablet with reliable content uniformity and rapid dissolution offers the clearest value. A formulation that also reduces reliance on specialized packaging or improves manufacturing yield could create a stronger commercial advantage than a simple excipient substitution.

References

1. Food and Drug Administration. (2015). FDA approves Genvoya for HIV-1 infection. U.S. Department of Health and Human Services.

2. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

3. Gilead Sciences, Inc. (2024). Genvoya prescribing information. Foster City, CA: Author.

4. Gilead Sciences, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Foster City, CA: Author.

5. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355.